mercaptopurine has been researched along with posaconazole* in 2 studies
2 other study(ies) available for mercaptopurine and posaconazole
| Article | Year |
|---|---|
Invasive mucormycosis during treatment for acute lymphoblastic leukaemia-successful management of two life-threatening diseases.
A 5-year-old patient treated for acute lymphoblastic leukaemia (ALL) developed proven pulmonary invasive fungal disease (IFD) due to Actinomucor elegans. While completing ALL treatment according to AIEOP ALL protocol 2009 for further 15 months, antifungal treatment with liposomal amphotericin B and intermittent additional posaconazole was continued until immune reconstitution 7 months after the end of ALL treatment. Repeated imaging guided treatment decisions. Twenty-six and 19 months after the end of ALL treatment and antifungal treatment, respectively, the patient is still in the first complete remission and shows no signs of active invasive fungal disease (IFD). Topics: Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Humans; Invasive Fungal Infections; Lung Diseases, Fungal; Male; Mercaptopurine; Methotrexate; Mucorales; Mucormycosis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Triazoles; Vincristine | 2020 |
Autologous transplantation of CD133 selected hematopoietic progenitor cells for treatment of relapsed acute lymphoblastic leukemia.
A 21-year-old white male with relapsed acute lymphoblastic leukemia (ALL) developed an invasive Zygomycosis infection 3 weeks after beginning re-induction chemotherapy. Because of the high risk of fatal recurrence of the fungal infection, neither long-term maintenance chemotherapy nor allogeneic hematopoietic stem cell transplant (HSCT) was considered appropriate. Because his ALL blasts expressed CD34 but lacked CD133, he received a CD133 selected autologous graft following high-dose consolidation chemotherapy. The patient survives in remission 19 months after HSCT. Topics: AC133 Antigen; Amphotericin B; Antifungal Agents; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Caspofungin; Child; Combined Modality Therapy; Contraindications; Dexamethasone; Drug Therapy, Combination; Echinocandins; Glycoproteins; Humans; Immunomagnetic Separation; Lipopeptides; Male; Mercaptopurine; Methotrexate; Peptides; Peptides, Cyclic; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Remission Induction; Salvage Therapy; Transplantation, Autologous; Transplantation, Homologous; Triazoles; Vincristine; Voriconazole; Zygomycosis | 2007 |